IART:NSD-Integra LifeSciences Holdings Corporation (USD)

COMMON STOCK | Medical Devices | NSD

Last Closing Price

USD 67.68

Change

0.00 (0.00)%

Market Cap

USD 5.72B

Volume

0.13M

Avg Analyst Target

USD 80.00 (+18.20%)

Avg User Target

USD
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict

About

Integra LifeSciences Holdings Corporation develops, manufactures, and markets surgical implants and medical instruments for use in neurosurgery, extremity reconstruction, orthopedics, and general surgery. It operates in two segments, Codman Specialty Surgical, and Orthopedics and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, hydrocephalus management systems, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as asset management software and support, and after-market services. It also sells approximately 40,000 instrument patterns, and surgical and lighting products to hospitals and surgery centers, as well as dental, podiatry, and veterinary offices. In addition, the company provides regenerative technology products for the treatment of acute and chronic wounds; and surgical tissue repair products for hernia repair, peripheral nerve repair and protection, and tendon repair. Further, it offers skin and wound repair, bone and joint fixation implants in the upper and lower extremities, and bone grafts products. The company offers its products directly through various sales forces and other distribution channels to the hospitals, integrated health networks, group purchasing organizations, clinicians, surgery centers, and health care providers in the United States, Europe, Asia Pacific, and internationally. Integra LifeSciences Holdings Corporation was incorporated in 1989 and is headquartered in Princeton, New Jersey.

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2021-10-16 )

Largest Industry Peers for Medical Devices

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
ALGN Align Technology Inc

N/A

USD46.66B 67.21 49.74
PODD Insulet Corporation

N/A

USD20.70B 2,208.27 247.98
ABMD Abiomed Inc

N/A

USD15.95B 103.89 50.66
LVGO Livongo Health, Inc

N/A

USD14.20B N/A N/A
BRKR Bruker Corporation

N/A

USD11.66B 49.76 25.84
TNDM Tandem Diabetes Care Inc

N/A

USD7.90B 1,216.99 251.84
SWAV ShockWave Medical Inc

N/A

USD6.92B N/A N/A
INMD InMode Ltd

N/A

USD6.51B 56.98 39.02
LIVN LivaNova PLC

N/A

USD4.46B 77.40 N/A
WMGI Wright Medical Group N.V

N/A

USD3.90B N/A 50.67

ETFs Containing IART

Symbol Name Weight Mer Price(Change) Market Cap
HTEC Robo Global Healthcare Te.. 0.00 % 0.68 %

N/A

USD0.24B

Market Performance

  Market Performance vs.
Industry/Classification (Medical Devices)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 4.25% 47% F 48% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 4.25% 47% F 46% F
Trailing 12 Months  
Capital Gain 39.66% 59% F 64% D
Dividend Return N/A N/A N/A N/A N/A
Total Return 39.66% 59% F 62% D-
Trailing 5 Years  
Capital Gain 235.26% 85% B 84% B
Dividend Return N/A N/A N/A N/A N/A
Total Return 235.26% 85% B 84% B
Average Annual (5 Year Horizon)  
Capital Gain 20.56% 44% F 66% D
Dividend Return N/A N/A N/A N/A N/A
Total Return 20.56% 44% F 65% D
Risk Return Profile  
Volatility (Standard Deviation) 40.26% 76% C 45% F
Risk Adjusted Return 51.06% 70% C- 69% D+
Market Capitalization 5.72B 92% A- 87% B+
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Medical Devices)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 28.04 51% F 33% F
Price/Book Ratio 3.58 58% F 38% F
Price / Cash Flow Ratio 28.08 18% F 16% F
EV/EBITDA 18.47 62% D- 40% F
Management Effectiveness  
Return on Equity 14.06% 92% A- 79% C+
Return on Invested Capital 6.69% 83% B 70% C-
Return on Assets 4.92% 90% A- 79% C+
Debt to Equity Ratio 92.96% 28% F 23% F
Technical Ratios  
Short Ratio 11.42 13% F 7% F
Short Percent 6.08% 29% F 29% F
Beta 1.25 48% F 42% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Ratings

Target Price Action Rating Action Analyst Rating Price Date

No discussions yet

User / Independent Analyst Ratings

User Name Target Rating Target Horizon (Months) Target Price User Analysis Date Comment

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters then its peers, placing it in the top quartile.

Superior capital utilization

The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Superior Earnings Growth

This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.

What to not like:
Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Highly leveraged

The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.